Take-home message {#FPar40}
=================

Persistent but not transient AKI (as defined according to the new "Acute Disease Quality Initiative Workgroup" definitions) independently contributes to short- and long-term mortality during sepsis. Compared to transient AKI, persistent AKI is associated with sustained systemic inflammation, coagulation activation and loss of vascular integrity.

Introduction {#Sec1}
============

Acute kidney injury (AKI) is a heterogeneous syndrome occurring in one out of two critically ill patients \[[@CR1]\], associated with increased short- and long-term mortality \[[@CR2]\], cardiovascular complications \[[@CR3]\], and persistent renal dysfunction \[[@CR4]\]. Sepsis is the main cause of AKI in intensive care units (ICUs), accounting for 50% of all cases \[[@CR2], [@CR5]\]. The complex pathophysiology of sepsis and the high burden of AKI in this context \[[@CR6], [@CR7]\] led to define the simultaneous presence of both syndromes as sepsis-associated AKI (S-AKI) \[[@CR8]\]. Except for renal replacement therapy \[[@CR9], [@CR10]\], no specific treatment exists to date.

Besides the severity of renal dysfunction \[[@CR11]\], various patterns of renal recovery may impact the outcome of S-AKI \[[@CR12]\]. Because the definition of recovery has been equivocal \[[@CR13]\], the Acute Disease Quality Initiative Workgroup (ADQI) recently proposed to further classify AKI as "transient" or "persistent" according to a duration of less or more than 48 hours, respectively \[[@CR14]\]. This definition is based on expert opinion and awaits clinical validation.

The singularity of S-AKI pathogenesis has been underlined by the description of normal to increased renal blood flow \[[@CR15]--[@CR18]\] and modest histopathological findings \[[@CR19]--[@CR22]\], contrasting with the long-standing theory of renal hypoperfusion-induced acute tubular necrosis \[[@CR23]\]. Experimental studies suggest a role for oxidative stress, inflammation \[[@CR24]\], microvascular shunting \[[@CR25]\], and tubular cell stress \[[@CR26]\], but data in patients are scarce and the influence of the unbalanced sepsis host response on recovery from S-AKI is unknown.

The primary objective of this study was to determine the incidence and mortality associated with transient and persistent AKI in critically ill patients admitted with sepsis using the new ADQI definitions \[[@CR14]\]. Additionally, we sought to determine differences in the host response to the inciting sepsis event between patients without AKI, and those with transient or persistent AKI by analysis of plasma biomarkers implicated in the pathogenesis of critical illness and whole-genome blood leukocyte transcriptomes.

This work was partially presented at the French Intensive Care Society international Congress on February 5--7, 2020, in Paris \[[@CR27]\].

Methods {#Sec2}
=======

Study design and population {#Sec3}
---------------------------

This study was part of the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) project, a prospective observational study conducted between January 2011 and December 2013 in the mixed ICUs of two tertiary teaching hospitals in the Netherlands (Academic Medical Center, Amsterdam and University Medical Center Utrecht, Utrecht; ClinicalTrials.gov identifier NCT01905033) \[[@CR28], [@CR29]\].

For the current analysis, all consecutive patients with sepsis older than 18 years of age and with an expected length of stay greater than 24 h were included via an opt-out consent method approved by the institutional review boards of both hospitals (IRB No. 10-056C). The plausibility of an infection was assessed daily using a four-point scale (ascending from none, possible, probable, to definite) \[[@CR28]\]. Readmissions and patients transferred from another ICU were excluded, except when patients were referred to one of the study centers the same day of presentation to the first ICU.

In additional analyses, patients with sepsis were compared with patients admitted to the ICU for a noninfectious condition originally selected as control groups for patients with pneumonia, abdominal sepsis, or septic shock \[[@CR30]--[@CR32]\].

Clinical variables and definitions {#Sec4}
----------------------------------

Sepsis was defined according to the new definition as the presence of an infection (with a likelihood of at least possible) diagnosed within 24 hours after ICU admission and organ dysfunction(s) represented by two or more Sequential Organ Failure Assessment (SOFA) points \[[@CR33]\]. The presence of AKI was assessed prospectively and daily, using the risk, injury, failure, loss, and end-stage kidney disease (RIFLE) classification \[[@CR34]\] based on maximum severity by either creatinine or urine output criteria. This definition used at the time of the study is concordant with the more recent Kidney Disease: Improving Global Outcomes (KDIGO) definition \[[@CR35], [@CR36]\] (Online resource eTable 1). When a recent reference creatinine value was not available, baseline creatinine was estimated using the MDRD equation by back calculation from an estimated glomerular filtration rate of 75 mL/min/1.73 m^2^ \[[@CR37]\].

AKI was defined as the presence of at least one criterion consistent with the risk (R), injury (I), or failure (F) stage within the first 48 hours after ICU admission; otherwise patients were classified as having no AKI. In accordance with recent expert consensus \[[@CR14]\], AKI was retrospectively classified as "persistent" if one or more RIFLE criteria remained present beyond 48 h from AKI onset, or if they normalized within 48 h but relapsed within the next 48 h. Reversal of RIFLE criteria within 48 h of AKI onset and for at least 48 h defined AKI as "transient". When 48-h follow-up was not possible due to death or discharge from ICU, AKI was classified as persistent if patients met one of the RIFLE criteria for their last measurement, otherwise as transient \[[@CR14]\].

For other definitions, see Online resource eMethods.

Biomarker assays and whole blood gene expression analyses {#Sec5}
---------------------------------------------------------

See online resource eMethods.

Statistical analyses {#Sec6}
--------------------

Baseline characteristics were compared with ANOVA for normally distributed and Kruskal--Wallis test for non-normally distributed continuous variables. Categorical data were analyzed using Chi-square or Fisher's exact test. Biomarker trajectories over time were analyzed using a general mixed model analysis in which a linear regression model was fitted on logarithmically transformed data, taking group (no AKI, transient AKI, persistent AKI), time, and their interaction as fixed effects, and patient-specific intercept and slope of time as random effects. Differences in biomarker distribution between groups at each time point were compared using Kruskal--Wallis tests followed by Dunn\'s post hoc tests.

To investigate the independent association between the presence and the evolution of AKI and mortality, we performed a logistic regression described in the online resource.

Receiver operating characteristic analyses, the handling of missing data, and sensitivity and subgroup analyses are described in the online resource.

Data analyses were performed in R (v 3.5.1, R Foundation for Statistical Computing, Vienna, Austria). Bonferroni multiple-comparison-adjusted *P* values less than .05 defined significance. Benjamini--Hochberg--adjusted *P* values defined significant differential gene expression and pathway enrichment.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

During the 3-year study period, 2787 consecutive ICU admissions for sepsis were included. A total of 1242 admissions were excluded, involving readmissions, transfers from other ICUs, patients with prior chronic kidney disease, or patients in whom the RIFLE score within the first 24 hours of ICU admission was not available (Online resource eFigure 1), resulting in a final study cohort of 1545 patients admitted with sepsis. Of these, 968 (62.7%) did not have AKI, while 577 (37.3%) were diagnosed with AKI within the first 48 h of admission (Table [1](#Tab1){ref-type="table"}). Of patients presenting with AKI, in 106 (18.4%) renal function recovered within 48 h of onset and for at least 48 h (transient AKI), and 471 (81.6%) had persistent AKI. Small differences were observed across study centers, likely related to differences in clinical presentation (Online resource, eTable 2).Table 1Baseline characteristics and outcomes of patients admitted to the ICU with sepsis, stratified according to the presence and evolution of acute kidney injuryNo AKI (*n* = 968)AKI*P* valueTransient AKI (*n* = 106)Persistent AKI (*n* = 471)***Demographics***Age, years62 \[48--71\]63 \[49--72\]65 \[54--73\]\*\< .001Male sex606 (62.6)61 (57.5)275 (58.4).23Race, white847 (88)90 (84.9)419 (90.3).21Medical admission721 (74.5)76 (71.7)340 (72.2).57***Chronic comorbidities***None318 (32.9)31 (29.2)135 (28.7).25Cardiovascular compromise229 (23.7)34 (32.1)127 (27).10Hypertension229 (23.7)35 (33.0)134 (28.5).030Diabetes159 (16.4)20 (18.9)92 (19.5).31Liver cirrhosis13 (1.3)4 (3.8)15 (3.2).021Immune compromise184 (19)18 (17)94 (20).79Malignancy200 (20.7)20 (18.9)114 (24.2).25Charlson comorbidity index3 \[1--5\]3 \[2--5\]3 \[2--5\]^\*^\< .001***Chronic medication***Diuretics185 (19.1)26 (24.5)120 (25.5)^\*^.016ACE inhibitors/ARBs223 (23)24 (22.6)128 (27.2).21Calcium-entry blockers122 (12.6)18 (17)68 (14.4).33Beta-adrenergic blockers222 (22.9)28 (26.4)135 (28.7).06NSAIDs and Cox II inhibitors112 (11.6)13 (12.3)52 (11).90Oral antidiabetic drugs113 (11.7)15 (14.2)67 (14.2).33Corticosteroids99 (10.2)9 (8.5)47 (10).90Antiplatelet drugs208 (22.5)24 (23.3)112 (24.5).71***Severity at time of admission to ICU***APACHE IV score67 \[52--85\]75 \[66--94\]^\*^95 \[74--118\]^\*†^\< .001Acute physiology score55 \[42--71\]64 \[54--80\]^\*^81 \[62--105\]^\*†^\< .001mSOFA score5 \[3--7\]8 \[6--9\]^\*^9 \[7--12\]^\*†^\< .001Non-renal mSOFA score5 \[3--7\]7 \[5--8\]^\*^8 \[6--9\]^\*†^\< .001Shock362 (37.4)73 (68.9)^\*^349 (74.1)^\*^\< .001ARDS192 (19.8)30 (28.3)135 (28.7)^\*^\< .001***Therapy during the first 24 h***Mechanical ventilation773 (79.9)89 (84)396 (84.1).13Vasopressors503 (52)83 (78.3)^\*^393 (83.4)^\*^\< .001Dose of vasopressors (mg)^a^5.8 \[2.0--13.3\]11.1 \[4.9--21.8\]^\*^15.1 \[5.6--33.5\]\*\< .001Inotropes40 (4.1)10 (9.4)^\*^82 (17.4)^\*†^\< .001Dose of inotropes (mg)^a^151.3 \[46.7--254.7\]126.4 \[57.5--303.8\]179.4 \[63.2--312.7\].52RRT6 (0.6)3 (2.8)^\*^98 (20.9)^\*†^\< .001Nephrotoxic drugs (≥ 1)379 (39.2)57 (53.8)^\*^280 (59.4)^\*^\< .001 Aminoglycoside128 (13.2)24 (22.6)^\*^129 (27.4)^\*^\< .001 Glycopeptide106 (11)12 (11.3)78 (16.6)^\*^.012 Colloid163 (16.8)30 (28.3)^\*^175 (37.2)^\*^\< .001      Other^b^94 (9.7)10 (9.4)37 (7.9).53***Source of infection***Pulmonary tract562 (58.1)54 (50.9)164 (34.8)^\*†^\< .001Abdominal134 (13.8)27 (25.5)^\*^129 (27.4)^\*^\< .001Cardiovascular70 (7.2)6 (5.7)64 (13.6)^\*^\< .001Urinary tract43 (4.4)6 (5.7)44 (9.3)^\*^.001CNS56 (5.8)3 (2.8)12 (2.5)^\*^.013Skin or soft tissue22 (2.3)4 (3.8)26 (5.5)^\*^.006Other^c^78 (8.1)6 (5.7)20 (4.2)^\*^.021Unknown3 (0.3)0 (0)12 (2.5)^\*^\< .001***Renal function during the first 24 h***Creatinine (µmol/L)79 \[60--102\]136 \[93--170\]^\*^175 \[131--246\]^\*†^\< .001Urea (mmol/L)6.7 \[4.6--9.9\]11.4 \[8.3--17.2\]^\*^13.2 \[9.4--19.1\]^\*^\< .001Bicarbonate, minimal (mmol/L)22.3 \[19.1--25.9\]18.9 \[16.9--22.8\]^\*^16.2 \[13.2--20.3\]^\*†^\< .001Urine output (mL)1900 \[1303--2815\]1405 \[1015--2440\]^\*^940 \[408--1643\]^\*†^\< .001***Outcome***Duration of initial MV (days)2 \[1--5\]3 \[1--7\]^\*^2 \[1--8\]^\*^\< .001Recurrence of MV24 (2.5)9 (8.5)^\*^24 (5.1)^\*^.001MV-free days^d^86 \[46--89\]84 \[30--88\]40 \[1--86\]^\*†^\< .001Use of RRT25 (2.6)6 (5.7)^\*^162 (34.4)^\*†^\< .001RRT-free days^d^90 \[59--90\]90 \[42--90\]55 \[3--90\]^\*†^\< .001Complications^*e*^ None870 (89.9)92 (86.8)403 (85.6).048 ICU-acquired AKI57 (5.9)4 (3.8)12 (2.5)^\*^.014 ICU-acquired ARDS20 (2.1)3 (2.8)10 (2.1).81 ICU-acquired infection47 (4.9)10 (9.4)^\*^56 (11.9)^\*^\< .001ICU length of stay (days)4 \[2--8\]6 \[4--9\]^\*^5 \[3--11\]^\*†^\< .001Hospital length of stay (days)16 \[8--29\]18 \[10--33\]15 \[5--34\].05ICU-mortality109 (11.3)13 (12.3)178 (37.8)^\*†^\< .00130-day mortality197 (20.4)21 (19.8)203 (43.1)^\*†^\< .00160-day mortality245 (25.3)29 (27.4)232 (49.3)^\*†^\< .00190-day mortality274 (28.3)31 (29.2)247 (52.4)^\*†^\< .0011-year mortality365 (37.7)40 (37.7)278 (59)^\*†^\< .001ICU-free days^d^84 \[45--87\]82 \[27--86\]47 \[0--84\]^\*†^\< .001*ACE* angiotensin-converting enzyme, *AKI* acute kidney injury, *APACHE* acute physiology and chronic health evaluation, *ARDS* acute respiratory distress syndrome, *ARBs* angiotensin II receptor blockers, *CNS* central nervous system, *ICU* intensive care unit, *MV* mechanical ventilation, *NSAIDs* non-steroidal anti-inflammatory drugs, *RRT* renal replacement therapy, *mSOFA* modified sequential organ failure assessment (excluding central nervous system component).Data presented as median \[interquartile range\], or *n* (%). Continuous variables were compared using the Kruskal--Wallis test. Associations between categorical variables were tested using the Fisher\'s exact test. *P* value represents comparisons between the three groups.^\*^Significant versus no AKI, using a Dunn's test of multiple comparisons using rank sums (continuous variables) or a pairwise test for a multi-level 2-dimensional matrix (categorical variables).^†^Significant versus transient AKI, using a Dunn's test of multiple comparisons using rank sums (continuous variables) or a pairwise test for a multi-level two-dimensional matrix (categorical variables).^a^Cumulative dose given for patients who received vasopressors (epinephrine, norepinephrine or dopamine, expressed in norepinephrine-equivalent dose) or dobutamine during the first 24 h^b^Other nephrotoxic drug; includes any of the following medications: nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, amphotericin B, acyclovir, foscarnet, calcineurin inhibitors.^c^Other sites of infection: infections of bones and joints (*n* = 19), oral infections (*n* = 8), postoperative wound infections (*n* = 20), upper respiratory tract infections (*n* = 20), viral systemic infections (*n* = 6), endometritis (*n* = 4), other (*n* = 27).^d^Between inclusion and day 90.^e^Complications were defined as ICU-acquired when diagnosed more than 48h after admission to the ICU.

Compared with patients without AKI, patients with AKI differed minimally in demographics, chronic comorbidities, or medications (Table [1](#Tab1){ref-type="table"}). Patients with persistent AKI were older, more often received diuretic therapy, and had a higher Charlson comorbidity index. Both transient and persistent AKI were strongly associated with the severity of disease, as reflected by higher APACHE IV scores, higher modified total and non-renal (m)SOFA scores, a more frequent occurrence of shock, ARDS, and requirement for inotropes and higher doses of vasopressors, when compared with absence of AKI (Table [1](#Tab1){ref-type="table"}). Exposure to nephrotoxic drugs was also more frequent in these patients (Table [1](#Tab1){ref-type="table"}).

Abdominal, cardiovascular, urinary tract, and skin or soft tissue infections were more prevalent in patients with persistent AKI (Table [1](#Tab1){ref-type="table"}), possibly related to a more severe disease presentation and more frequent use of nephrotoxic drugs (data not shown). Gram-negative bacteria and yeasts were more frequently identified in this group (Online resource eTable 3).

Severity and evolution of AKI {#Sec9}
-----------------------------

Persistent AKI was associated with more severe renal dysfunction at baseline, as reflected by higher urea and creatinine concentrations and a lower urine output compared with transient AKI (Table [1](#Tab1){ref-type="table"}). 33 (31.3%) of patients with a persistent AKI had mild (none or R) RIFLE criteria, whereas 149 (31.1%) of patients with a transient AKI fulfilled severe (I or F) criteria at the time of admission (Fig. [1](#Fig1){ref-type="fig"}a--e). Median creatinine levels stayed within the normal range in patients without AKI on admission, as well as in patients with transient AKI after the first 48 h. In patients with persistent AKI, median creatinine levels remained elevated for up to 28 days (Fig. [1](#Fig1){ref-type="fig"}f).Fig. 1Evolution of acute kidney injury in patients with sepsis. **a** Chord diagrams depicting the relationship between the severity of AKI upon ICU-admission and the subsequent presence and evolution of AKI over the first 48 hours. The bottom part of the diagram represents patients ranked by initial RIFLE score calculated upon ICU admission, and the top part represents the same patients ranked according to the presence and evolution of AKI over the first 48 h (no AKI, transient or persistent AKI). Ribbons show for every patient the connection between the initial RIFLE score and the subsequent evolution of AKI. The first diagram (**a**) represents all patients combined. The diagrams below (**b**--**e**), highlight each individual RIFLE severity score separately. Admission RIFLE score was "none" for all (*n* = 968) patients without AKI. Of patients with transient AKI, 13 (12.3%), 60 (56.6), 24 (22.6), and 9 (8.5%) had an admission RIFLE score of "none," "at risk," "injury," or "failure," respectively. Of patients who developed persistent AKI, 39 (8.3%), 110 (23.4%), 147 (31.2%), and 175 (37.2%) had an admission RIFLE score of "none", "at risk", "injury", or "failure", respectively. **f** Plasma creatinine over time stratified according to the evolution of AKI after admission to the intensive care unit (ICU). Data are presented as mean and standard error of the mean. Numbers below axes indicate the number of patients still present in the ICU for each group. *Note*: mean creatinine levels showed small increases at day 8 and day 20 in the transient AKI group due to the occurrence of ICU-acquired AKI in 4 patients in whom renal function initially recovered after the initial episode of AKI

Outcome {#Sec10}
-------

Compared with patients without AKI, patients with transient or persistent AKI had a longer ICU length of stay and were more prone to develop an ICU-acquired infection (Table [1](#Tab1){ref-type="table"}). Patients with persistent AKI had a reduced number of days alive and free from mechanical ventilation, free from renal replacement therapy, or out of the ICU. Mortality at day 30 increased along with AKI severity on admission (Online resource eFigure 2). In addition, patients with persistent AKI, but not with transient AKI showed increased mortality in the ICU and up to one year after admission (Table [1](#Tab1){ref-type="table"}, Online resource eFigure 3).

In a logistic regression analysis, persistent but not transient AKI was associated with an increased crude risk of mortality by day 30 and up to 1 year compared with no AKI (Table [2](#Tab2){ref-type="table"}, Online resource eTable 4). After adjustment for severity and other confounding factors, the specific association between the persistence of AKI and 30-day mortality (OR 2.42, 95% CI 1.28-- 4.58; *P*= .006, Table [2](#Tab2){ref-type="table"}) and 1-year mortality (OR 2.10, 95% CI 1.12--3.92; *P*= .020, Online resource eTable 4) remained. The Hosmer--Lemeshow test showed proper model calibration (Online resource eFigure 4).Table 2Logistic regression analysis evaluating the influence of the evolution of acute kidney injury on 30-day mortalityOdds ratio (95% CI)*P* valueWald test *χ*^2^ (df)*P****Crude model***^a^No AKI1 (reference)--82.4 (2)*P*\< .001Transient AKI0.97 (0.58--1.6).90Persistent AKI2.96 (2.33--3.77)\< .001***Adjusted model***^b^No AKI1 (reference)--10.5 (2)*P*= .005Transient AKI1.25 (0.58--2.7).56Persistent AKI2.42 (1.28--4.58).006*AKI* acute kidney injury, *CI* confidence interval, *df* degrees of freedom.^a^Unadjusted model.^b^Adjusted for age, admission RIFLE score, APACHE acute physiology score, source of infection, and modified Charlson comorbidity index (omitting the age parameter).

Plasma renal function and host response biomarkers {#Sec11}
--------------------------------------------------

Biomarkers indicative of renal function and host response pathways implicated in sepsis pathogenesis were measured on admission to the ICU and at day 2 and day 4 thereafter in the subset of sepsis patients with a definite or probable infection likelihood enrolled during the first 2.5 years (*n* = 866, 56%). This subgroup was comparable to the whole cohort (Online resource eTable 5).

The plasma levels of cystatin C and neutrophil gelatinase-associated lipocalin (NGAL) have been used as markers of renal function \[[@CR38]--[@CR40]\]. Both cystatin C and NGAL were elevated in patients with sepsis compared with healthy volunteers irrespective of the presence of AKI, and further increased in patients with AKI compared with patients without AKI (Online resource eFigure 5). On admission, cystatin C but not NGAL concentrations were significantly higher in patients who went on to have a persistent AKI compared with those in whom AKI was transient (*P*\< .001).

Patients with sepsis showed typical features of a dysregulated host response \[[@CR41], [@CR42]\] (Fig. [2](#Fig2){ref-type="fig"}). Compared with patients without renal dysfunction, patients with transient and persistent AKI had higher levels of interleukin (IL)-6, IL-8, IL-10, and matrix metalloproteinase-8 on admission. Patients with persistent AKI, but not with transient AKI, also had more prominent signs of endothelial cell activation (elevated plasma levels of fractalkine, soluble E-selectin, soluble intercellular adhesion molecule-1), more severe loss of vascular integrity (increased angiopoietin-2/angiopoietin-1 ratio), and stronger activation of the coagulation system (prolonged prothrombin time and activated partial thromboplastin time, elevated plasma levels of D-dimer, and reduced platelet counts and levels of natural anticoagulants antithrombin and protein C); these aberrations persisted up until day 4 (Fig. [2](#Fig2){ref-type="fig"}, Online resource, eTable 6). Similarly, blood leukocytes were higher in patients with transient and persistent AKI (Online resource eFigure 6). Differences at admission, albeit significant, did not make these biomarkers individually suitable for the early prediction of evolution towards persistent AKI (Online resources, eTable 7).Fig. 2Host response biomarkers in patients with sepsis during the first 4 days of ICU stay stratified according to the evolution of acute kidney injury after admission. Biological parameters are classified as **a** inflammatory responses, **b** endothelial cell activation, and **c** coagulation activation biomarkers. Data are presented as box and whiskers, as specified by Tukey. Dotted lines represent median values obtained in 27 healthy age-matched healthy subjects. Overall *P* values were derived from the linear mixed model in which the group, or the interaction of time x group (i.e. the trajectory) were defined as fixed effects, and patient-specific intercept and slopes were defined as random effects. Comparisons between groups at specific days were performed using the Kruskal--Wallis test followed by Dunn\'s post hoc tests of multiple comparisons using rank sums. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001, \*\*\*\**P* \< .0001. AKI, acute kidney injury; ANG, angiopoietin; aPTT, activated partial thromboplastin time; IL, interleukin; MMP, matrix metalloproteinase; PT, prothrombin time; sE-Selectin, soluble E-selectin; sICAM, soluble intercellular adhesion molecule

Whole blood leukocyte transcriptome analysis {#Sec12}
--------------------------------------------

In the subgroup of sepsis patients with an infection likelihood of definite or probable enrolled during the first 1.5 years of the study period, blood leukocyte genome-wide RNA profiles were determined on admission (*n* = 392, of whom 225 without AKI, 36 with transient AKI and 131 with persistent AKI) (Online resource eTable 8). Blood RNA profiles of patients were initially compared to those of 42 healthy controls. Both patients without and with AKI displayed strong blood transcriptome alterations, encompassing 71--80% of all genes present on the array (Fig. [3](#Fig3){ref-type="fig"}a). Of the altered RNA transcripts, 79% were common to patients without AKI and those with transient or persistent AKI (Fig. [3](#Fig3){ref-type="fig"}b) and this common response showed strongly correlated gene expression fold changes (Fig. [3](#Fig3){ref-type="fig"}c). Consistent with earlier studies in sepsis patients \[[@CR29], [@CR43]\], pathway analysis of the common response revealed a typical overexpression of genes involved in both pro- and anti-inflammatory innate immune responses and metabolic pathways, and a concomitant underexpression of genes of lymphocyte and antigen presentation pathways (Online resource eFigure 7). Direct comparison of transcriptomes between patients without, transient, or persistent AKI showed no or minimal statistically significant differences (Fig. [3](#Fig3){ref-type="fig"}d). Only the comparison of persistent to no AKI revealed a global decrease in expression of genes involved in key innate and adaptive immune cell functions, concomitant with increased expression of specific metabolic pathway genes (Online resource eFigure 8).Fig. 3Leukocyte genomic responses upon admission in sepsis patients without, transient, or persistent acute kidney injury. **a** Volcano plots illustrating the differences in leukocyte genomic responses (integrating log2 fold changes and multiple-test adjusted probabilities) between sepsis patients without acute kidney injury (AKI) on admission and healthy subjects (left), between patients with transient AKI and healthy subjects (center), and between patients with persistent AKI and healthy subjects (right). Considering adjusted *P* \< .05, 9037, 8303 and 9467 genes were identified as differentially expressed in patients without AKI, patients with transient AKI and patients with persistent AKI on admission vs healthy subjects, respectively. Blue dots represent significantly underexpressed genes (adjusted *P* \< .05, fold expression \< −1.5), whereas red dots represent significantly overexpressed genes (adjusted *P* \< .05, fold expression \> 1.5) in patients relative to healthy controls. Horizontal dotted line indicates multiple-test adjusted Benjamini--Hochberg (BH) *P* \< .05 threshold. Within plots, pie charts show the extent of gene expression changes: Blue slices show significantly underexpressed genes (adjusted *P* \< .05 and expression more than 1.5-times decreased compared with healthy controls), red slices show significantly overexpressed genes (adjusted *P* \< .05 and expression more than 1.5-time increased compared with healthy controls), and grey slices show significantly different gene expression (adjusted *P* \< .05 and expression less than 1.5-time increased or decreased compared with healthy controls). **b** Venn--Euler representation of differentially expressed genes on admission in sepsis patients without, transient or persistent AKI vs healthy subjects (adjusted *P* \< .05). Red arrows denote overexpressed genes; blue arrows denote underexpressed genes. **c** Dot plot depicting the common response (log2 fold changes) of patients without, transient, or persistent AKI as compared with healthy subjects. Rho, Spearman's correlation coefficient. **d** Volcano plot illustrating the differences in leukocyte genomic responses on admission between patients with transient AKI relative to patients without AKI (left), between patients with persistent AKI relative to patients without AKI (center), and between patients with persistent AKI relative to patients with transient AKI (right). Considering adjusted *P* \< .05, no gene was differentially expressed in patients with transient AKI versus no AKI and in patients with persistent AKI vs transient AKI, and 2466 genes were differentially expressed between patients with persistent AKI vs patients without AKI. Within plots, pie charts show the extent of gene expression changes compared to the control group

Subgroup and sensitivity analyses {#Sec13}
---------------------------------

Multiple subgroup and sensitivity analyses were performed to assess the robustness of the analyses presented above (Online resources, eResults).

These analyses focused on patients still present in the ICU on day 4 (Online resource eTables 10, 11, eFigure 9), patients matched for severity and baseline differences (Online resource eTables 12, 13), patients with shock (Online resource eTables 14--24, eFigures 10--13), and patients with severe (RIFLE I-F) AKI (Online resources eTables 25--28, eFigure 14).

Additionally, we investigated the impact of alternative cutoffs to define persistent AKI (Online resource eTables 29--36, eFigures 15--16) and described a group of patients with noninfectious admission diagnoses (Online resource eTables 37--40, eFigures 17--19)

These additional analyses largely confirmed the findings in the primary cohort.

Discussion {#Sec14}
==========

In this prospectively enrolled cohort of critically ill patients with sepsis, we used the new ADQI consensus definitions of transient and persistent AKI \[[@CR14]\] to determine the incidence of distinct AKI trajectories and the mortality associated with the persistence of AKI. More than a third of sepsis patients had AKI upon ICU admission, of which the majority was severe (RIFLE stage I or F), and persistent in 4 out of every 5 patients. In contrast to transient AKI, persistent AKI independently impacted patient outcome, with more than twofold increased odds for 30-day mortality when compared with no AKI. This study further suggests that besides the severity of AKI, the duration of renal dysfunction independently affects short-term and up to 1-year patient survival. Aside from the sepsis-related sustained disturbance of homeostasis \[[@CR44]\], the persistence of AKI may specifically impact patient survival through prolonged exposure to harmful adverse events, such as fluid overload, electrolyte and acid-base disturbances, cardiovascular events \[[@CR3]\], and the development of chronic kidney disease \[[@CR45], [@CR46]\]. Our data are in agreement with findings of previous investigations based on retrospective calculation of AKI severity scores \[[@CR3], [@CR47], [@CR48]\], using different definitions for renal recovery ranging from 24 h to hospital discharge \[[@CR7], [@CR12], [@CR47]--[@CR51]\], or using ICU or hospital mortality as primary outcomes \[[@CR47]--[@CR49]\].

The various patterns of renal recovery after AKI thus far have been mainly attributed to the severity of the underlying disease or of the AKI itself \[[@CR13]\]. Except knowledge derived from experimental studies and postmortem observations, little is known about the pathophysiological processes responsible for the onset and persistence of kidney dysfunction during sepsis. In a subgroup of patients, we measured 16 host response biomarkers reflective of important pathways involved in the pathogenesis of sepsis, during the first 4 days after ICU admission. The presence of AKI was associated with enhanced inflammatory responses upon admission. Interestingly, whereas cytokine levels normalized by day 4 in patients with transient AKI, the persistence of AKI was associated with sustained inflammatory responses along the first four days. In addition, patients who went on to experience persistent AKI demonstrated stronger endothelial cell and coagulation activation and a more profound loss of vascular integrity early from admission until day 4, whereas patients with a transient AKI did not differ from patients without AKI. Although our study does not prove causality, the remaining sustained hyperinflammation and loss of vascular integrity in patients with persistent AKI after matching for severity support a possible role of these host response pathways in the course of AKI during human sepsis. Experimental investigations support the hypothesis implicating inflammation and endothelial dysfunction in the pathogenesis of S-AKI \[[@CR52]--[@CR56]\]. Leukocyte transcriptomic responses showed minimal differences with respect to the presence or persistence of AKI. Notably, this finding does not exclude a role for leukocytes that have migrated into renal tissue, a possibility that is difficult to investigate in large clinical cohorts such as described here. Similar host response abnormalities were also found in patients admitted for noninfectious condition, suggesting that analogous pathophysiological phenomena may be involved in the more general context of critical illness.

Our study has strengths and limitations. This is the first evaluation of the recent ADQI consensus definitions for transient and persistent AKI \[[@CR14]\], done in a large, well-characterized cohort of sepsis patients. Daily RIFLE scores were collected prospectively, providing a more accurate estimation of renal function than retrospective severity score calculations \[[@CR57]\]. The sequential measurements of plasma biomarkers during the first four ICU days provide valuable insights into the trajectories of the host response to sepsis and renal function. Multiple subgroup and sensitivity analyses strengthened the robustness of our conclusions. Limitations include the retrospective classification of the evolution of AKI, the frequent difficulty to determine the exact timing of organ dysfunction in sepsis patients, which requires to deem ICU-admission the onset of AKI, and the lack of clinical and biological data beyond ICU stay, which precludes adequate assessment of the persistence of AKI beyond day 7, defining acute kidney disease \[[@CR14]\]. Although data were collected several years ago (2011--2013), guidelines for the management of AKI and use of renal replacement therapy have not changed since then \[[@CR35], [@CR58], [@CR59]\].

Conclusions {#Sec15}
===========

In patients with sepsis, persistent AKI is independently associated with short- and long-term mortality. Sepsis-induced loss of vascular integrity and sustained inflammation may contribute to the persistence of AKI.
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